Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NATURE'S BOUNTY FOURTH-QUARTER SALES JUMP 46% TO $ 42.1 MIL.

This article was originally published in The Tan Sheet

Executive Summary

NATURE'S BOUNTY FOURTH-QUARTER SALES JUMP 46% TO $ 42.1 MIL. while net income more than doubled to $ 4.5 mil. for the three- month period ended Sept. 30, the Bohemia, N.Y.-based supplement manufacturer announced Nov. 19. Nature's Bounty reported a 37% sales gain to $ 138.4 mil. for all of fiscal 1993. Net earnings for the year grew 157% to $ 9.8 mil., compared with fiscal 1992 earnings of $ 3.8 mil. "Over the past year, we have successfully increased sales to existing customers and attracted new customers through all our channels of distribution," commented Nature's Bounty Chairman and CEO Scott Rudolph, who recently succeeded his father, Arthur Rudolph, as chairman. "Furthermore, we significantly improved our operational and manufacturing efficiencies." In an Aug. 18 prospectus covering a stock offering by Arthur Rudolph, Nature's Bounty said it manufactures approximately 55% of all its supplements but expects "to increase such percentage substantially by December 1993." The company also said that it was planning to pursue new chainstore customers in the western U.S., as well as deepen distribution through its existing wholesale, retail, and mail order channels ("The Tan Sheet" Aug. 30, p. 17). Scott Rudolph said Nature's Bounty is entering fiscal 1994 "with a growing customer base, a technologically advanced manufacturing and production facility, and an improved balance sheet with over $ 101 mil. in total assets and $ 70 mil. in stockholders' equity." Chart omitted.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel